Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Risk Factors of Cerebral Vein and Sinus Thrombosis
Front Neurol Neurosci 23:23-54, de Freitas, G.R. & Bogousslavsky, J., 2008
Cerebral Sinus Thrombosis with Tamoxifen
Neurol 56:1113-1114, Finelli,P.F. & Schauer,P.K., 2001
Neuroimaging Findings in Children and Young Adults with Neurotoxicity after CAR T-Cell Therapy for B-Cell Malignancies
Neurol 105:e214086, McGuire,J.L.,et al, 2025
Vitamin B12 Deficiency:NICE Guideline Summary
BMJ 385:q1019, q1262, Sands,T.,et al, 2024
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Disparities and Guideline Adherence in Drugs of Abuse Screening in Intracerebral Hemorrhage
Neurol 88:252-258, Tomoehlen, L.M.,et al, 2017
Intracranial Meningeal Enhancement Characterization
Rev Colomb Radiol 28:4709-4716, Mera, J.L.C.,et al, 2017
Cytotoxic Lesions of the Corpus Callosum That Show Restricted Diffusion: Mechanisms, Causes, and Manifestations
RadioGraphics 37:562-576, Starkey, J.,et al, 2017
Dystonia in Children and Adolescents: A Systematic Review and a New Diagnostic Algorithm
JNNP 86:774-781, Van Egmond, M.E.,et al, 2015
Multimodal Imaging of Reversible Cerebral Vasoconstriction Syndrome: A Series of 6 Cases
AJNR 33:1403-1410, Marder, C.P.,et al, 2012
Spectrum of Neurologic Complications in Chronic Lymphocytic Leukemia
Clin Lymphoma Myeloma Leuk 12:164-179, Lopes da Silva, R., 2012
Reversible Cerebral Vasoconstruction Syndromes
Arch Neurol 68:1005-1012,976, Singhal, A.B.,et al, 2011
Fast-In, Fast-Out
Lancet 373:1398, Hefele,B.,et al, 2009
Delayed Leukoencephalopathy with Stroke-Like Presentation in Chemotherapy Recipients
JNNP 79:535-539, Baehring,J.M. &Fulbright,R.K., 2008
Narrative Review: Reversible Cerebral Vasoconstriction Syndromes
Ann Intern Med 146:34-44, Calabrese,L.H.,et al, 2007
The Clinical and Radiological Spectrum of Reversible Cerebral Vasoconstriction Syndrome. A Prospective Series of 67 Patients
Brain 130:3091-3101, Ducros, A.,et al, 2007
Statin-Associated Myasthenia Gravis
Medicine 85:82-85, Purvin,V.,et al, 2006
Dystonia
NEJM 355:818-829, Tarsy,D. &Simon,D.K., 2006
Clinicopath Conf, Strychnine Poisoning, Case 12-2001
NEJM 344:1232-1239, , 2001
Cerebral Venous Thrombosis Associated with Epoetin Alfa Therapy
Arch Neurol 57:260-262, Finelli,P.F.&Carley,M.D., 2000
Adverse Cardiovascular and Central Nervous System Events Associated with Dietary Supplements Containing Ephedra Alkaloids
NEJM 343:1833-1838,1886, Haller,C.A. & Benowitz,N.L., 2000
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
Opsoclonus
Semin Neurol 16:21-26, Averbuch-Heller,L.&Remler,B., 1996
Neurologic Manifestations of Cocaine Exposure in Childhood
Pediatrics 93:557-560, Mott,S.H.,et al, 1994
Reversible Neurologic Toxicity with Fludarabine Phosphate for Mycosis Fungiodes & Chronic Lymphocytic Leukemia
Ann Int Med 118:114-116, Cohen,R.B.,et al, 1993
Phenobarbital Rheumatism in Patients with Brain Tumor
Ann Neurol 25:92-94, Taylor,L.P.&Posner,J.B., 1989
Azathioprine Toxicity During Long-Term Immunosuppression of Generalized Myasthenia Gravis
Neurol 38:258-261, Hohlfeld,R.,et al, 1988
Retinitis Pigmentosa
Surv Ophthalmol 33:137-177, Pagon,R.A., 1988
Opsoclonus in Adults
Arch Neurol 43:1165-1175, Digre,K.B., 1986
Hypoglycemia:Fact or Fiction
Mayo Clin Proc 60:844-850, Nelson,R.L., 1985
The Neurotoxicity of Antibacterial Agents
Ann Int Med 101:92-104, Snavely,S.R.,et al, 1984
Beta-Adrenoreceptor Antagonists & Diplopia
Lancet 2:826-827, Weber,J.C.P., 1982
Disorders of Neuromuscular Transmission Caused by Drugs
NEJM 301:409-413, Argov,Z.,et al, 1979